RU2014135436A - Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака - Google Patents
Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака Download PDFInfo
- Publication number
- RU2014135436A RU2014135436A RU2014135436A RU2014135436A RU2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- groups
- unsubstituted
- group
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593047P | 2012-01-31 | 2012-01-31 | |
| US61/593,047 | 2012-01-31 | ||
| PCT/US2013/023781 WO2013116293A1 (en) | 2012-01-31 | 2013-01-30 | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014135436A true RU2014135436A (ru) | 2016-03-27 |
Family
ID=47679114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014135436A RU2014135436A (ru) | 2012-01-31 | 2013-01-30 | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140378422A1 (https=) |
| EP (1) | EP2809312A1 (https=) |
| JP (1) | JP2015505562A (https=) |
| KR (1) | KR20140117457A (https=) |
| CN (1) | CN104093402A (https=) |
| AU (1) | AU2013215251A1 (https=) |
| BR (1) | BR112014017985A8 (https=) |
| CA (1) | CA2861377A1 (https=) |
| IN (1) | IN2014DN05869A (https=) |
| MX (1) | MX2014009303A (https=) |
| RU (1) | RU2014135436A (https=) |
| WO (1) | WO2013116293A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507964A (ja) * | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
| ES2887148T3 (es) | 2015-03-25 | 2021-12-21 | Nat Cancer Ct | Agente terapéutico contra el cáncer de vías biliares |
| SMT202300018T1 (it) | 2015-12-09 | 2023-03-17 | Univ Illinois | Downregolatori del recettore degli estrogeni a base di benzotiofene |
| US12414945B2 (en) | 2015-12-17 | 2025-09-16 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| MA51570A (fr) * | 2018-01-10 | 2020-11-18 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du carcinome hépatocellulaire |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| SG11202007591RA (en) | 2018-03-28 | 2020-09-29 | Eisai R&D Man Co Ltd | Therapeutic agent for hepatocellular carcinoma |
| TWI841598B (zh) * | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| US20220023300A1 (en) * | 2018-11-26 | 2022-01-27 | Taiho Pharmaceutical Co., Ltd. | Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy |
| CA3185174A1 (en) * | 2020-07-31 | 2022-02-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| WO2022184146A1 (zh) * | 2021-03-03 | 2022-09-09 | 正大天晴药业集团股份有限公司 | Cdk4/6抑制剂的联用药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (https=) | 1962-09-13 | |||
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| CZ304344B6 (cs) | 2000-09-11 | 2014-03-19 | Novartis Vaccines & Diagnostics, Inc. | Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu |
| ITTV20030095A1 (it) | 2003-07-14 | 2005-01-15 | Asolo Spa | Calzatura con sottopiede composito. |
| CN102225926A (zh) | 2003-11-07 | 2011-10-26 | 诺华疫苗和诊断公司 | 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐 |
| KR101387985B1 (ko) * | 2005-01-27 | 2014-04-25 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 전이 종양의 치료 |
| CA2608171C (en) * | 2005-05-13 | 2014-02-04 | Novartis Ag | Use of quinolinone compounds for treating drug resistant cancers |
| MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
| RU2433826C2 (ru) | 2005-11-29 | 2011-11-20 | Новартис Аг | Композиции хинолинонов |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
-
2013
- 2013-01-30 JP JP2014555661A patent/JP2015505562A/ja active Pending
- 2013-01-30 IN IN5869DEN2014 patent/IN2014DN05869A/en unknown
- 2013-01-30 MX MX2014009303A patent/MX2014009303A/es unknown
- 2013-01-30 KR KR1020147021140A patent/KR20140117457A/ko not_active Ceased
- 2013-01-30 AU AU2013215251A patent/AU2013215251A1/en not_active Abandoned
- 2013-01-30 CA CA2861377A patent/CA2861377A1/en not_active Abandoned
- 2013-01-30 BR BR112014017985A patent/BR112014017985A8/pt not_active Application Discontinuation
- 2013-01-30 WO PCT/US2013/023781 patent/WO2013116293A1/en not_active Ceased
- 2013-01-30 EP EP13703295.9A patent/EP2809312A1/en not_active Withdrawn
- 2013-01-30 RU RU2014135436A patent/RU2014135436A/ru unknown
- 2013-01-30 CN CN201380006947.7A patent/CN104093402A/zh active Pending
- 2013-01-30 US US14/375,145 patent/US20140378422A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014017985A8 (pt) | 2017-07-11 |
| US20140378422A1 (en) | 2014-12-25 |
| BR112014017985A2 (https=) | 2017-06-20 |
| WO2013116293A1 (en) | 2013-08-08 |
| IN2014DN05869A (https=) | 2015-05-22 |
| MX2014009303A (es) | 2014-10-14 |
| AU2013215251A1 (en) | 2014-08-14 |
| JP2015505562A (ja) | 2015-02-23 |
| CA2861377A1 (en) | 2013-08-08 |
| EP2809312A1 (en) | 2014-12-10 |
| KR20140117457A (ko) | 2014-10-07 |
| CN104093402A (zh) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| RU2018106453A (ru) | Соединения | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| RU2016134751A (ru) | Соединения | |
| JP2019510832A5 (https=) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| JP2013528600A5 (https=) | ||
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| MX372814B (es) | Dihidronaftiridinas y compuestos relacionados útiles como inhibidores cinasas para el tratamiento de enfermedades proliferativas. | |
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| JP2013507415A5 (https=) | ||
| RU2013155586A (ru) | [1,3]оксазины | |
| SI2953948T1 (en) | Fluorinated integrin antagonists | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2015535247A5 (https=) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2016522254A5 (https=) | ||
| JP2015522033A5 (https=) | ||
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| RU2012135698A (ru) | Способ и композиция |